Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10407764 | 0.79 | — | — | |
| SCHEMBL4767808 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL220757 | 0.73 | — | — | |
| SCHEMBL1206364 | 0.70 | L3MBTL1 (0.53) | NPC1RAB9A | |
| SCHEMBL5851070 | 0.69 | — | — | |
| SCHEMBL10585144 | 0.69 | — | — | |
| SCHEMBL11580343 | 0.69 | — | — | |
| SCHEMBL5178129 | 0.69 | — | — | |
| SCHEMBL1411653 | 0.69 | — | — | |
| SCHEMBL6709739 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326696-B2 | Amino-methyl substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| CN-1302016-C | Fulvene, metallocene catalysts and preparation method thereof, and preparation of polyolefines copolymer using the same | LG CHEMICAL LTD (KR) | 2007-02-28 | — | — | CN | disclosed |
| CN-1578792-A | Methylene cyclopentadiene, metallocene catalyst, method for preparing the same, and method for preparing polyolefin copolymer using the same | LG CHEMICAL LTD (KR) | 2005-02-09 | — | — | CN | disclosed |
| US-5750552-A | ANTIULCER AGENTS | ARAX CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0736527-A1 | Imadazoline derivative, possible tautomer thereof, process of manufacturing therefor, and vulnerary including such derivative or tautomer | ARAX CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | ATM 3559/4885IDO1 1011/4885CCNE2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.